Alto NeuroscienceANRO +1.57%12 Market Cap is $887.88 Mil as of Jun. 25, 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,431 Biotechnology companies, Alto Neuroscience ranks better than 78.9% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alto Neuroscience's share price for the quarter that ended in Mar. 2026 was $22.48. Alto Neuroscience's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 35.05 Mil. Therefore, Alto Neuroscience's market cap for the quarter that ended in Mar. 2026 was $787.99 Mil.
Alto Neuroscience's quarterly market cap
increased
from Sep. 2025 ($109.22 Mil) to Dec. 2025 ($568.25 Mil) and
increased
from Dec. 2025 ($568.25 Mil) to Mar. 2026 ($787.99 Mil).
Alto Neuroscience's annual market cap
increased
from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($114.16 Mil) and
increased
from Dec. 2024 ($114.16 Mil) to Dec. 2025 ($568.25 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alto Neuroscience's Enterprise Value for Today is $647.33 Mil.
Alto Neuroscience (NYSE:ANRO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Alto Neuroscience Market Cap Related Terms
Alto Neuroscience Market Cap Historical Data
* Premium members only.
The historical data trend for Alto Neuroscience's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alto Neuroscience's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alto Neuroscience Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alto Neuroscience's Market Cap distribution charts can be found below:
* The bar in red indicates where Alto Neuroscience's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Alto Neuroscience's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alto Neuroscience (ANRO) has a Market Cap of $887.88 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alto Neuroscience and its competitors. According to the industry distribution chart, Alto Neuroscience ranks #302 out of 1431 companies in the Biotechnology industry, placing it in the top 21.1%.
Is Alto Neuroscience's Market Cap too high?
Alto Neuroscience's current Market Cap is $887.88 Mil. The Biotechnology industry median Market Cap is 117.63. Alto Neuroscience's value of $887.88 Mil is 654.8% above this industry median. Based on the distribution chart, Alto Neuroscience ranks #302 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's Market Cap compare to MRVI and BBOT?
According to the Biotechnology industry distribution chart, Alto Neuroscience ranks #302 out of 1431 companies for Market Cap. This places Alto Neuroscience in the top 21% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.63. Alto Neuroscience's value of $887.88 Mil is 654.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alto Neuroscience's current Market Cap of $887.88 Mil is 654.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alto Neuroscience and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alto Neuroscience's current Market Cap is $887.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current Market Cap of $887.88 Mil. The current Market Cap is $887.88 Mil and 654.8% above the Biotechnology industry median of 117.63. Alto Neuroscience's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current Market Cap is $887.88 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score
Get the complete analysis for ANRO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANRO has been successfully added to your 
